Zaki Abou Zahr
Zaki Abou Zahr has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Salman Bin Mahmood
Department of Internal Medicine Hennepin Healthcare Minneapolis MN USA
1 shared publication Sb Mahmood
Department of Internal Medicine, Hennepin Healthcare, Minneapolis, MN, USA
1 shared publicationYi Peng
Chronic Disease Research Group Hennepin Healthcare Research Institute Minneapolis MN USA
1 shared publicationYuanyuan Ji
Chronic Disease Research Group Hennepin Healthcare Research Institute Minneapolis MN USA
1 shared publication
Latest Publications
- 5 November 2020
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 24 (1) , 63-68
Incidence of giant cell arteritis after bisphosphonate exposure: A retrospective cohort study
Objectives Bisphosphonates may cause autoimmune reactions via a cytokine‐mediated acute phase response. A case of giant cell arteritis (GCA) after zoledronate injection was recently reported. We aimed to evaluate this association by reviewing the incidence of GCA after bisphosphonate administration. Methods This was a retrospective study using the medical claims data of elderly patients in the 20% Medicare random sample from 2008‐2014 who had received zoledronate or ibandronate. Patients who had a diagnosis claim of GCA within the past year before receiving either bisphosphonate were excluded. The development of GCA was assessed in 2 ways: GCA diagnosis claim within 28 days of bisphosphonate injection and another claim within 90 days of initial claim; and temporal artery biopsy claim within 28 days of bisphosphonate injection and GCA diagnosis claim within 90 days of biopsy. Due to the Centers for Medicare & Medicaid Services reporting requirements we excluded numbers less than 11 from analysis. Results The incidence of GCA was 0.010% and 0.013% after zoledronate and ibandronate injection respectively. In the zoledronate group incidence was highest in patients aged 75‐85 years (0.011%), in Whites (0.011%), in the northeast census region (0.013%) and higher in females (0.011% vs 0.009%). All GCA cases noted in the ibandronate group involved White females. We are unable to report incidences by age and region due to the paucity of data. Conclusion The incidence of GCA after bisphosphonate injection was not increased compared to the generally reported incidence in the USA.
- 5 November 2020
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 24 (1) , 63-68
Incidence of giant cell arteritis after bisphosphonate exposure: A retrospective cohort study
Objectives Bisphosphonates may cause autoimmune reactions via a cytokine‐mediated acute phase response. A case of giant cell arteritis (GCA) after zoledronate injection was recently reported. We aimed to evaluate this association by reviewing the incidence of GCA after bisphosphonate administration. Methods This was a retrospective study using the medical claims data of elderly patients in the 20% Medicare random sample from 2008‐2014 who had received zoledronate or ibandronate. Patients who had a diagnosis claim of GCA within the past year before receiving either bisphosphonate were excluded. The development of GCA was assessed in 2 ways: GCA diagnosis claim within 28 days of bisphosphonate injection and another claim within 90 days of initial claim; and temporal artery biopsy claim within 28 days of bisphosphonate injection and GCA diagnosis claim within 90 days of biopsy. Due to the Centers for Medicare & Medicaid Services reporting requirements we excluded numbers less than 11 from analysis. Results The incidence of GCA was 0.010% and 0.013% after zoledronate and ibandronate injection respectively. In the zoledronate group incidence was highest in patients aged 75‐85 years (0.011%), in Whites (0.011%), in the northeast census region (0.013%) and higher in females (0.011% vs 0.009%). All GCA cases noted in the ibandronate group involved White females. We are unable to report incidences by age and region due to the paucity of data. Conclusion The incidence of GCA after bisphosphonate injection was not increased compared to the generally reported incidence in the USA.
- 15 April 2020
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 49 (6) , 507-508
Systemic lupus erythematosus triggered by trimethoprim–sulfamethoxazole
(2020). Systemic lupus erythematosus triggered by trimethoprim–sulfamethoxazole. Scandinavian Journal of Rheumatology. Ahead of Print.
- 15 April 2020
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 49 (6) , 507-508
Systemic lupus erythematosus triggered by trimethoprim–sulfamethoxazole
(2020). Systemic lupus erythematosus triggered by trimethoprim–sulfamethoxazole. Scandinavian Journal of Rheumatology. Ahead of Print.